Fed. Circ. Could Ease On-Sale Bar Threat To Pharma Patents
The full Federal Circuit will hear arguments Thursday in a patent case over the blood-thinning drug Angiomax that could narrow the reach of the on-sale bar and protect companies from invalidity...To view the full article, register now.
Already a subscriber? Click here to view full article